DamianoAbeniMD, MPHMichaelBigbyMDPaoloPasquiniMD, MPHMoysesSzkloMD, MPH, DrPHHywelWilliamsMSc, PhD, FRCP
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanomaPoo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid ACCancer. 1999;86:2252-2258.
More than 44,000 new cases of melanoma are detected annually in the United States, and the number is steadily increasing. The majority of patients are treated with surgical excision and may, in addition, undergo sentinel node mapping, lymph node dissection, and adjunctive treatment. The purpose of this study was to develop rational, evidence-based guidelines for following up patients with 1983 American Joint Committee on Cancer stage I (<1.5 mm thick), II (localized disease >1.5 mm thick), and III (local nodal or in-transit metastases) melanoma.
Chartier T, Bigby M. Rational Follow-up Recommendations for Patients With Melanoma. Arch Dermatol. 2000;136(9):1145-1148. doi:10.1001/archderm.136.9.1145